So Ha Lee

Dr. So Ha Lee


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2010 in Medicinal Research Reviews
Verified
Journal Article
Closed access
PDF file
IEIbrahim El-Deeb
Ibrahim El-Deeb
KYKyung Ho Yoo
Kyung Ho Yoo
SLSo Ha Lee
So Ha Lee

1 August 2014 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
BPByung Sun Park
Byung Sun Park
MAMohammad Alsanea
Mohammad Alsanea
AAAhmed Z. Abdelazem
Ahmed Z. Abdelazem
HPHye Mi Park
Hye Mi Park
EREun Joo Roh
Eun Joo Roh
SLSo Ha Lee
So Ha Lee

1 September 2013 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
BPB. S. Park
B. S. Park
AAA. Z. Abdel-Azeem
A. Z. Abdel-Azeem
MAMohammad Alsanea
Mohammad Alsanea
KYK. H. Yoo
K. H. Yoo
JTJ. S. Tae
J. S. Tae
SLSo Ha Lee
So Ha Lee
In 1977 an unknown natural product was isolated from Streptomyces staurosporeus by Omura et al. during a search for new alkaloids present in actinomycetes and was given the name AM-2282. Later, the structure of AM-2282 was elucidated by single crystal X-ray analysis and renamed as staurosporine. It has been published that staurosporine and its analogues display strong inhibitory effect against a variety of kinases and a number of biological properties such as antifungal, antibacterial, and immunosuppressive activities. Despite strong inhibitory activity of staurosporine, a very high level of cross-reactivity makes it impossible to use staurosporine as a therapeutic agent. In the course of searching for other staurosporine-related compounds, a number of staurosporine analogues have been isolated from different microorganisms. In addition, a number of staurosporine analogues have been synthesized to improve the poor selectivity and target specificity of staurosporine which limited its clinical effectiveness. The review addresses staurosporine analogues from both microbial and synthetic sources and their biological activities.

9 January 2015 in Molecules
Verified
Journal Article
Open access
PDF file
MAMohammad Alsanea
Mohammad Alsanea
AEAhmed Elkamhawy
Ahmed Elkamhawy
AZAhmed Zakaria
Ahmed Zakaria
BPByung Sun Park
Byung Sun Park
YKYoungjoo Kwon
Youngjoo Kwon
IKIn Tae Kim
In Tae Kim
A series of phenylbipyridinylpyrazoles was synthesized through the reaction of 2-(4-(2-chloropyridin-4-yl)-3-(3-methoxy-5-methylphenyl)-1H-pyrazol-1-yl)acetonitrile (4) with different 6-substituted pyridine-3-ylboronic acids. The final compounds 5a–j were screened at 10 µM against over 60 tumor cell lines at the U.S. National Cancer Institute (NCI). In light of the NCI results, compounds 5c and 5h showed a broad spectrum of activity against NCI cell lines with mean growth of 53% and 58%, respectively. Compound 5e behaved differently as it showed high degree of selectivity and potency by inhibiting 96% of growth of leukemia SR cell line at 10 µM. Standard COMPARE analyses were performed at the GI50 level and the results exhibit high correlation in the form of pairwise correlation coefficient (PCC) of more than 0.6 between three of the current compounds and three standard known anticancer agents. Compound 5e demonstrated high correlation levels with merbarone (NSC S336628) with a PCC value of 0.631. Compound 5h showed a considerably high PCC value of 0.626 with dichloroallyl lawsone, while compound 5i, showed PCC values of 0.601 and 0.604 with both dichloroallyl lawsone and N,N-dibenzyldaunomycin (NSC S268242), respectively. These three standard agents have anticancer activity via two major mechanism of actions, inhibition of topoisomerase II and inhibition of biosynthesis of pyrimidine nucleotides, therefore, compounds 5a–j are promising therapeutic agents for targeting different human malignancies. Prediction of drug-likeness and toxicity of these newly synthesized derivatives were also considered.

14 January 2016 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
MAMohammad Alsanea
Mohammad Alsanea
AAA.Z. Abdelazem
A.Z. Abdelazem
BPB.S. Park
B.S. Park
KYK.H. Yoo
K.H. Yoo
TST. Sim
T. Sim
SLSo Ha Lee
So Ha Lee
ROS1 is a pivotal transmembrane receptor protein tyrosine kinase which regulates several cellular processes like apoptosis, survival, differentiation, proliferation, cell migration, and transformation. There is increasing evidence supporting that ROS1 plays an important role in different malignancies including glioblastoma, colorectal cancer, gastric adenocarcinoma, inflammatory myofibroblastic tumor, ovarian cancer, angiosarcoma, and non small cell lung cancer; thus, ROS1 has become a potential drug discovery target. ROS1 shares about 49% sequence homology with ALK primary structure; therefore, wide range of ALK kinase inhibitors have shown in vitro inhibitory activity against ROS1 kinase. After Crizotinib approval by FDA for the management of ALK-rearranged lung cancer, ROS1-positive tumors have been focused. Although significant advancements have been achieved in understanding ROS1 function and its signaling pathways plus recent discovery of small molecules modulating ROS1 protein, a vital need of medicinal chemistry efforts is still required to produce selective and potent ROS1 inhibitors as an important therapeutic strategy for different human malignancies. This review focuses on the current knowledge about different scaffolds targeting ROS1 rearrangements, methods to synthesis, and some biological data about the most potent compounds that have delivered various scaffold structures.

1 January 2015 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AAAhmed Z. Abdelazem
Ahmed Z. Abdelazem
MAMohammad Alsanea
Mohammad Alsanea
BPByung Sun Park
Byung Sun Park
HPHye Mi Park
Hye Mi Park
KYKyung Ho Yoo
Kyung Ho Yoo
SLSo Ha Lee
So Ha Lee